+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Enoxaparin"

Low Molecular Weight Heparin Global Market Report 2024 - Product Thumbnail Image

Low Molecular Weight Heparin Global Market Report 2024

  • Report
  • August 2024
  • 175 Pages
  • Global
From
Myocardial Infarction Global Market Report 2024 - Product Thumbnail Image

Myocardial Infarction Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Heparin Global Market Report 2024 - Product Thumbnail Image

Heparin Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020 - Product Thumbnail Image

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 35 Pages
  • Global
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Enoxaparin is a cardiovascular drug used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a low molecular weight heparin (LMWH) that works by preventing the formation of blood clots. Enoxaparin is administered by subcutaneous injection and is available in both generic and branded forms. It is often used in combination with other anticoagulants such as warfarin. Enoxaparin is also used to reduce the risk of stroke and heart attack in patients with acute coronary syndrome. Enoxaparin is a widely used drug in the cardiovascular market and is available in many countries around the world. It is often prescribed as a first-line treatment for DVT and PE, and is also used in the prevention and treatment of other cardiovascular conditions. Some companies in the Enoxaparin market include Sanofi, Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more